Drug Search Results
More Filters [+]

BSI-075

Alternative Names: BSI-075, BSI075, BSI 075
Latest Update: 2023-03-28
Latest Update Note: Clinical Trial Update

Product Description

BSI-075 is an anti-PVRIG humanized antibody with high selectivity and high affinity. It demonstrated 10x higher binding affinity to PVRIG and 3x higher cell-based bioactivity compared to a COM701 analog. Inhibiting PVRIG leads to enhanced activation of T and NK cells and results in tumor growth inhibition. Biosion has global rights to develop and commercialize BSI-075. (Sourced from: https://www.biosion.com/pipeline)

Mechanisms of Action: PVRIG Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biosion
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BSI-075

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title